Ultraprocessed Food Increases Risk for Death With Type 2 Diabetes
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, Aug. 2, 2023 -- Higher consumption of ultraprocessed food (UPF) is associated with lower survival and higher cardiovascular mortality in patients with type 2 diabetes, according to a study published online July 26 in the American Journal of Clinical Nutrition.
Marialaura Bonaccio, Ph.D., from the IRCCS Istituto Neurologico Mediterraneo Neuromed in Pozzilli, Italy, and colleagues evaluated the association of UPF intake with all-cause and cardiovascular disease (CVD) mortality among 1,065 participants with type 2 diabetes followed for a median of 11.6 years.
The researchers found that greater UPF intake (quartile 4: ≥10.5 percent of total food eaten for women and ≥9 percent for men) versus the lowest (quartile 1: UPF <4.7 and <3.7 percent for women and men, respectively), was associated with a higher risk for both all-cause (hazard ratio, 1.70) and CVD mortality (hazard ratio, 2.64). Associations were not substantially changed with inclusion of the Mediterranean diet score in the model (hazard ratios, 1.64 and 2.55 for all-cause and CVD mortality, respectively). There was a linear dose-response relationship observed between UPF intake with both all-cause and CVD mortality.
"Besides prioritizing the adoption of a diet based on nutritional requirements, dietary guidelines for the management of type 2 diabetes should also recommend limiting UPF," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.